The revenue of Alembic Pharma was mainly driven by the API segment, which grew by 65% YoY to INR 3260mn, whereas posted sequential growth of 11% during the quarter. The growth in the segment was aided by improved product mix and high offtake. Furthermore, the company anticipates 10-15% YoY increase in this segment in FY24.